
Genentech Updates sBLA for Columvi Combo in R/R DLBCL
Genentech Receives FDA Complete Response Letter for Columvi Combination Therapy in Second-Line Diffuse Large B-Cell Lymphoma; Reaffirms Commitment to Advancing Columvi Across the Treatment Landscape Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the…











